Selective use of sandostatin in vascularized pancreas transplantation

Robert J. Stratta, Rodney J. Taylor, Jeffrey A. Lowell, J. Stevenson Bynon, Mark Cattral, Alan N. Langnas, Byers W. Shaw

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Despite improving results, the management of exocrine complications after pancreas transplantation remains problematic. During a 30-month period, we performed 65 pancreas transplants with bladder drainage. A total of 23 patients (35%) were managed with a long-acting somatostatin analogue (Sandostatin) for persistent hyperamylasemia or allograft pancreatitis. Sandostatin was begun at a mean of 29 days after transplant with a mean duration of therapy of 13 days. Sandostatin therapy was associated with significant reductions in the serum, urine, and peritoneal fluid amylase levels (p<0.05). Sandostatin also caused a decrease in cyclosporine levels during oral cyclosporine use. In patients receiving Sandostatin, pancreas allograft survival was 83%. We conclude that pancreatitis remains a major cause of morbidity after pancreas transplantation. The selective use of Sandostatin can result in excellent graft salvage with low morbidity. Sandostatin appears to be safe and effective in reducing the exocrine output of the denervated pancreas allograft but also reduces cyclosporine levels.1From the Department of Surgery, University of Nebraska Medical Center and Bishop Clarkson Memorial Hospital, Omaha, Nebraska.

Original languageEnglish (US)
Pages (from-to)598-605
Number of pages8
JournalThe American Journal of Surgery
Volume166
Issue number6
DOIs
StatePublished - Dec 1993

Fingerprint

Pancreas Transplantation
Octreotide
Cyclosporine
Allografts
Pancreas
Transplants
Pancreatitis
Hyperamylasemia
Morbidity
Ascitic Fluid
Amylases
Somatostatin
Drainage
Urinary Bladder
Urine
Therapeutics
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

Stratta, R. J., Taylor, R. J., Lowell, J. A., Bynon, J. S., Cattral, M., Langnas, A. N., & Shaw, B. W. (1993). Selective use of sandostatin in vascularized pancreas transplantation. The American Journal of Surgery, 166(6), 598-605. https://doi.org/10.1016/S0002-9610(05)80663-4

Selective use of sandostatin in vascularized pancreas transplantation. / Stratta, Robert J.; Taylor, Rodney J.; Lowell, Jeffrey A.; Bynon, J. Stevenson; Cattral, Mark; Langnas, Alan N.; Shaw, Byers W.

In: The American Journal of Surgery, Vol. 166, No. 6, 12.1993, p. 598-605.

Research output: Contribution to journalArticle

Stratta, RJ, Taylor, RJ, Lowell, JA, Bynon, JS, Cattral, M, Langnas, AN & Shaw, BW 1993, 'Selective use of sandostatin in vascularized pancreas transplantation', The American Journal of Surgery, vol. 166, no. 6, pp. 598-605. https://doi.org/10.1016/S0002-9610(05)80663-4
Stratta, Robert J. ; Taylor, Rodney J. ; Lowell, Jeffrey A. ; Bynon, J. Stevenson ; Cattral, Mark ; Langnas, Alan N. ; Shaw, Byers W. / Selective use of sandostatin in vascularized pancreas transplantation. In: The American Journal of Surgery. 1993 ; Vol. 166, No. 6. pp. 598-605.
@article{aa0758d4bce64078a030f5a7b9695b66,
title = "Selective use of sandostatin in vascularized pancreas transplantation",
abstract = "Despite improving results, the management of exocrine complications after pancreas transplantation remains problematic. During a 30-month period, we performed 65 pancreas transplants with bladder drainage. A total of 23 patients (35{\%}) were managed with a long-acting somatostatin analogue (Sandostatin) for persistent hyperamylasemia or allograft pancreatitis. Sandostatin was begun at a mean of 29 days after transplant with a mean duration of therapy of 13 days. Sandostatin therapy was associated with significant reductions in the serum, urine, and peritoneal fluid amylase levels (p<0.05). Sandostatin also caused a decrease in cyclosporine levels during oral cyclosporine use. In patients receiving Sandostatin, pancreas allograft survival was 83{\%}. We conclude that pancreatitis remains a major cause of morbidity after pancreas transplantation. The selective use of Sandostatin can result in excellent graft salvage with low morbidity. Sandostatin appears to be safe and effective in reducing the exocrine output of the denervated pancreas allograft but also reduces cyclosporine levels.1From the Department of Surgery, University of Nebraska Medical Center and Bishop Clarkson Memorial Hospital, Omaha, Nebraska.",
author = "Stratta, {Robert J.} and Taylor, {Rodney J.} and Lowell, {Jeffrey A.} and Bynon, {J. Stevenson} and Mark Cattral and Langnas, {Alan N.} and Shaw, {Byers W.}",
year = "1993",
month = "12",
doi = "10.1016/S0002-9610(05)80663-4",
language = "English (US)",
volume = "166",
pages = "598--605",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Selective use of sandostatin in vascularized pancreas transplantation

AU - Stratta, Robert J.

AU - Taylor, Rodney J.

AU - Lowell, Jeffrey A.

AU - Bynon, J. Stevenson

AU - Cattral, Mark

AU - Langnas, Alan N.

AU - Shaw, Byers W.

PY - 1993/12

Y1 - 1993/12

N2 - Despite improving results, the management of exocrine complications after pancreas transplantation remains problematic. During a 30-month period, we performed 65 pancreas transplants with bladder drainage. A total of 23 patients (35%) were managed with a long-acting somatostatin analogue (Sandostatin) for persistent hyperamylasemia or allograft pancreatitis. Sandostatin was begun at a mean of 29 days after transplant with a mean duration of therapy of 13 days. Sandostatin therapy was associated with significant reductions in the serum, urine, and peritoneal fluid amylase levels (p<0.05). Sandostatin also caused a decrease in cyclosporine levels during oral cyclosporine use. In patients receiving Sandostatin, pancreas allograft survival was 83%. We conclude that pancreatitis remains a major cause of morbidity after pancreas transplantation. The selective use of Sandostatin can result in excellent graft salvage with low morbidity. Sandostatin appears to be safe and effective in reducing the exocrine output of the denervated pancreas allograft but also reduces cyclosporine levels.1From the Department of Surgery, University of Nebraska Medical Center and Bishop Clarkson Memorial Hospital, Omaha, Nebraska.

AB - Despite improving results, the management of exocrine complications after pancreas transplantation remains problematic. During a 30-month period, we performed 65 pancreas transplants with bladder drainage. A total of 23 patients (35%) were managed with a long-acting somatostatin analogue (Sandostatin) for persistent hyperamylasemia or allograft pancreatitis. Sandostatin was begun at a mean of 29 days after transplant with a mean duration of therapy of 13 days. Sandostatin therapy was associated with significant reductions in the serum, urine, and peritoneal fluid amylase levels (p<0.05). Sandostatin also caused a decrease in cyclosporine levels during oral cyclosporine use. In patients receiving Sandostatin, pancreas allograft survival was 83%. We conclude that pancreatitis remains a major cause of morbidity after pancreas transplantation. The selective use of Sandostatin can result in excellent graft salvage with low morbidity. Sandostatin appears to be safe and effective in reducing the exocrine output of the denervated pancreas allograft but also reduces cyclosporine levels.1From the Department of Surgery, University of Nebraska Medical Center and Bishop Clarkson Memorial Hospital, Omaha, Nebraska.

UR - http://www.scopus.com/inward/record.url?scp=0027755961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027755961&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(05)80663-4

DO - 10.1016/S0002-9610(05)80663-4

M3 - Article

C2 - 7506009

AN - SCOPUS:0027755961

VL - 166

SP - 598

EP - 605

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 6

ER -